Please assess the completion status of the following clinical trial:

Trial Title: Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years,~* Liver failure as defined by a Child-Pugh score ≥ 10 points,~* Accept to participate,~* Have health insurance.~Exclusion Criteria:~* Pregnancy,~* Patient who has been treated with a quinolone in the month before his inclusion~* Allergy to quinolones,~* Hepatocellular carcinoma, and~* HIV infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Norfloxacin (Type: ACTIVE_COMPARATOR): Patients with severe cirrhosis treated with norfloxacin
- Placebo (Type: PLACEBO_COMPARATOR): Patients with severe cirrhosis treated with placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).